R&D News | pharmaphorum

News

Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials.

News

Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.

News

Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.

News

One in six common bacterial infections in people worldwide in 2023 were resistant to antibiotic treatments, according to the WHO.

News

UCB's experimental medicine for TK2d, currently under regulatory review, offers hope to patients with the devastating rare disease.

News

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.